| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2-Bromo-6-nitrophenol is not a drug and does not have a direct pharmacological target. It is a synthetic intermediate used in the preparation of pharmaceutical compounds. When incorporated into the synthesis of Eltrombopag derivatives, the final product targets the Thrombopoietin (Tpo) receptor (also known as c-Mpl), a cytokine receptor that regulates megakaryocyte differentiation and platelet production. Eltrombopag is a small molecule agonist of the Tpo receptor.
|
|---|---|
| ln Vitro |
2-Bromo-6-nitrophenol has no intrinsic biological activity as a drug; its "activity" is purely chemical. It serves as a precursor in the synthesis of N-Hydroxy Eltrombopag, which is an analogue of the active pharmaceutical ingredient Eltrombopag. In the context of synthetic chemistry, it undergoes various reactions, such as nucleophilic aromatic substitution and metal-catalyzed coupling, to build more complex molecular scaffolds. The compound is available in high purity (≥98%) and is a crystalline solid.
|
| ln Vivo |
In vivo activity is not applicable. 2-Bromo-6-nitrophenol is not intended for administration to animals or humans. Its role is exclusively as a chemical building block in the laboratory. The therapeutic effects and in vivo efficacy are associated with the final drug products derived from this intermediate (e.g., Eltrombopag), which increase platelet counts in patients with immune thrombocytopenia (ITP) by acting as a thrombopoietin receptor agonist.
|
| Enzyme Assay |
2-Bromo-6-nitrophenol is a chemical intermediate, not a drug candidate for an enzyme or receptor binding assay. However, a typical non-cellular analytical method for this compound is High-Performance Liquid Chromatography (HPLC) to check its purity. A standard HPLC method uses a C18 reversed-phase column, a mobile phase of acetonitrile/water (e.g., 60:40), detection at a UV wavelength of 254 nm, and a flow rate of 1.0 mL/min. The retention time and peak area are compared to a reference standard.
|
| Cell Assay |
There are no standard cell-based assays for 2-Bromo-6-nitrophenol, as it lacks biological activity. However, it may be used in cellular assays indirectly after being conjugated or converted into a bioactive molecule. For instance, if the compound is incorporated into a PROTAC (proteolysis-targeting chimera), the final PROTAC product can be assessed in cells for degradation of the target protein. However, 2-Bromo-6-nitrophenol itself is not tested on cells. The compound is considered a building block with no direct biological effects.
|
| Animal Protocol |
2-Bromo-6-nitrophenol is not used directly in animal experiments as a therapeutic agent. It is strictly a synthetic intermediate. In studies where the target is Thrombopoietin receptor agonists, the final drug (e.g., Eltrombopag or its derivatives) would be tested in animal models such as a mouse model of thrombocytopenia. For example, mice are treated with anti-platelet antibodies to induce low platelet counts, then treated with the test compound (e.g., Eltrombopag) at doses of 10-30 mg/kg via oral gavage, and platelet counts are measured over time. However, the intermediate 2-Bromo-6-nitrophenol itself would not be administered.
|
| ADME/Pharmacokinetics |
2-Bromo-6-nitrophenol has a molecular weight of 218.00 and a molecular formula of C6H4BrNO3. It has a predicted LogP of approximately 2.2-2.6, indicating moderate lipophilicity. It is a solid with a melting point of 66-70degC and a density of 1.88 g/cm3. The compound is stable as a powder at -20degC for up to 3 years. For storage, it should be kept at -20degC under dry conditions. It has limited solubility in water but is soluble in organic solvents such as DMSO, ethanol, and acetonitrile.
|
| Toxicity/Toxicokinetics |
2-Bromo-6-nitrophenol is classified as a harmful chemical with acute oral toxicity. The GHS hazard statement is H302: Harmful if swallowed (97.87% of suppliers). Precautionary measures include avoiding inhalation, ingestion, and skin contact. It should be handled in a well-ventilated area or fume hood, using appropriate personal protective equipment (gloves, goggles, lab coat). The signal word for this compound is "Warning". It should be stored in a tightly sealed container, away from oxidizing agents.
|
| References |
[1]. D B Harper, et al. Studies on plant growth-regulating substances. 31. The metabolism of certain 2,6-disubstituted phenols within plant tissues. Ann Appl Biol. 1971 Apr;67(3):395-408.
|
| Additional Infomation |
2-Bromo-6-nitrophenol (CAS 13073-25-1) is a key intermediate used in the synthesis of Eltrombopag derivatives for the treatment of thrombocytopenia. Eltrombopag is a small molecule non-peptide thrombopoietin receptor agonist that is FDA-approved for the treatment of immune thrombocytopenia (ITP), aplastic anemia, and hepatitis C-associated thrombocytopenia. The bromo and nitro groups provide sites for further synthetic modifications, such as palladium-catalyzed cross-coupling reactions. This compound is strictly a research and industrial chemical, not a drug, and is not intended for therapeutic use.
|
| Molecular Formula |
C6H4BRNO3
|
|---|---|
| Molecular Weight |
218.01
|
| Exact Mass |
216.937
|
| CAS # |
13073-25-1
|
| PubChem CID |
13545453
|
| Appearance |
Light brown to yellow solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
227.2±20.0 °C at 760 mmHg
|
| Melting Point |
66-70 °C(lit.)
|
| Flash Point |
91.2±21.8 °C
|
| Vapour Pressure |
0.1±0.5 mmHg at 25°C
|
| Index of Refraction |
1.652
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
158
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C([N+]([O-])=O)C(=C(Br)C=C1)O
|
| InChi Key |
VEJSIOPQKQXJAT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H4BrNO3/c7-4-2-1-3-5(6(4)9)8(10)11/h1-3,9H
|
| Chemical Name |
2-bromo-6-nitrophenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (458.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5869 mL | 22.9347 mL | 45.8695 mL | |
| 5 mM | 0.9174 mL | 4.5869 mL | 9.1739 mL | |
| 10 mM | 0.4587 mL | 2.2935 mL | 4.5869 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
